The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Practical considerations when treating patients with WM: exciting agents & combinations
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses practical considerations when treating patients with Waldenström’s macroglobulinemia (WM), highlighting promising therapies available for patients. Dr Treon also comments on the importance of optimizing BTK inhibitor use and the sequencing of novel agents to improve outcomes for these patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
